Haemophilia trials in Germany

In Germany 29 Also abroad 128

29 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
Where
Berlin, Bonn, Frankfurt Am Main, Freiburg im Breisgau, Hamburg, Hanover
Age
12 years and over
People
360 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07416604 · EU 2025-522435-33-00
Phase 3Taking people
A Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia A
Where
Berlin, Bonn, Hanover, Leipzig, Regensburg
Age
18 years and over
People
84 worldwide
Run by
Novo Nordisk A/S
See details and how to joinNCT07830732 · EU 2026-525529-19-00
Phase 3Taking people
Efanesoctocog alfa treatment in patients with congenital hemophilia A suffering from inflammation of joint lining
Where
Berlin, Bonn, Dresden, Duisburg, Frankfurt am Main, Frankfurt Am Main, Giessen, Hamburg, Hanover, Homburg, Kiel, Leipzig, Regensburg
Age
18 years and over
People
60 worldwide
Run by
GWT-Tud GmbH
See details and how to join2025-523896-44-00 · EU 2025-523896-44-00
Phase 3Taking people
A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B
Where
Munich
Age
1 year to 11 years
People
85 worldwide
Run by
Sanofi
See details and how to joinNCT07285460 · EU 2025-521858-42-00
Phase 3Taking people
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
Where
Berlin
Age
1 year to 74 years
People
245 worldwide
Run by
Pfizer
See details and how to joinNCT05145127 · EU 2022-500470-33-00
Phase 3Taking people
A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A
Where
Berlin, Bonn, Frankfurt Am Main, Freiburg im Breisgau, Hanover
Age
12 years and over
People
138 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07416526 · EU 2025-522434-32-00
Phase 3Taking people
A Non-Investigational Product, Multi-Center Cohort Study to Describe Long-Term Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec
Where
Berlin, Bonn
Age
18 years to 64 years
People
32 worldwide
Run by
Pfizer Inc.
See details and how to join2025-523660-21-00 · EU 2025-523660-21-00
Phase 1/2Taking people
A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B
Where
Bonn, Frankfurt Am Main, Hamburg
Age
2 years and over
People
130 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT06379789 · EU 2023-507260-40-00
Phase 3Taking people
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
Where
Berlin
Age
1 year to 17 years
People
100 worldwide
Run by
Pfizer
See details and how to joinNCT05611801 · EU 2022-500495-65-00
Phase 3Taking people
Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
Where
Bonn
Age
18 years and over
People
173 worldwide
Run by
Pfizer
See details and how to joinNCT05568719
No phaseEnrolling by invitation
Patient Preferences in Treatment of Haemophilia A With and Without Inhibitors: a Discrete Choice Experiment in Germany
Where
Mainz
Age
18 years and over
People
150
Run by
Novo Nordisk A/S
See details and how to joinNCT07653139
Phase 4Taking people
Treatment of Hemophilia A Patients With FVIII Inhibitors
Where
Bonn, Duisburg, Frankfurt am Main, Giessen, Muenster
People
120 worldwide
Run by
Emory University
See details and how to joinNCT04023019 · EU 2024-516741-39-00
Phase 1Taking people
A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A
Where
Berlin, Bonn, Hanover
Age
18 years to 64 years
People
30 worldwide
Run by
Novo Nordisk A/S
See details and how to joinNCT07220564 · EU 2025-520490-38-00
Phase 4Taking people
Nuwiq Dosing and outcomes In the ManagEment of women/girls with haemophilia A Needing FVIII treatment for Surgery – an International, Open-label, Non-controlled study (NuDIMENSION)
Where
Bonn, Hamburg
People
17 worldwide
Run by
Octapharma AG
See details and how to join2022-502061-17-00 · EU 2022-502061-17-00
No phaseEnrolling by invitation
A Study Following Males With Haemophilia B on Prophylaxis With Refixia/REBINYN
Where
Berlin, Bonn
People
60 worldwide
Run by
Novo Nordisk A/S
See details and how to joinNCT03745924
No phaseTaking people
Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients
Where
Berlin, Bonn, Duisburg, Essen, Frankfurt
People
200 worldwide
Run by
Octapharma
See details and how to joinNCT03695978
Phase 4Taking people
Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study
Where
Berlin, Duisburg, Hamburg
Age
12 years and over
People
28 worldwide
Run by
Octapharma
See details and how to joinNCT05935358
Phase 4Taking people
Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery
Where
Bonn, Duisburg, Hamburg
Age
12 years and over
People
28 worldwide
Run by
Octapharma
See details and how to joinNCT05936580
No phaseTaking people
A Survey on the Success of Inhibitor Elimination Using Individualized Concentrate Selection and Controlled ITI
Where
Frankfurt am Main
People
300
Run by
Haemophilia Centre Rhine Main
See details and how to joinNCT02207894
No phaseTaking people
An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B
Where
Berlin, Bonn, Frankfurt, Hanover
Age
18 years and over
People
500 worldwide
Run by
CSL Behring
See details and how to joinNCT06008938
Phase 4Enrolling by invitation
A Long-Term Follow-Up Study in Severe Hemophilia A Subjects Who Received BMN 270 in a Prior BioMarin Clinical Trial (270-401)
Where
Berlin, Bonn
Age
18 years and over
People
172 worldwide
Run by
BioMarin Pharmaceutical
See details and how to joinNCT05768386 · EU 2023-507749-27-00
No phaseEnrolling by invitation
A Study Following Males With Haemophilia A on Prophylaxis With Esperoct®
Where
Berlin, Bonn
People
60 worldwide
Run by
Novo Nordisk A/S
See details and how to joinNCT04574076
No phaseEnrolling by invitation
Feasibility and Safety of Blood-Flow-Restriction Training in Patients With Hemophilia
Where
Bonn
Age
18 years and over
People
12
Run by
University Hospital, Bonn
See details and how to joinNCT07259356
Phase 4Taking people
Nuwiq for Perioperative management Of patients With haemophilia A on Emicizumab Regular prophylaxis study (NuPOWER)
Where
Berlin, Hamburg
People
45 worldwide
Run by
Octapharma AG
See details and how to join2022-502060-21-00 · EU 2022-502060-21-00
No phaseTaking people
The European Paediatric Network for Haemophilia Management ( PedNet Registry)
Where
Berlin, Bonn, Bremen, Frankfurt, Frankfurt am Main, Munich
People
4,000 worldwide
Run by
PedNet Haemophilia Research Foundation
See details and how to joinNCT02979119